Abstract
Characteristic symptoms of schizophrenia and bipolar disorders have been described and classified about a century ago. Each of these disorders may cause considerable impairment reflecting substantial alterations in cognition, perception, and mood. Though both disease concepts are well established, psychopharmacological treatment strategies, involving first- and second-generation antipsychotics, benzodiazepines and mood stabilizing drugs, often fail to keep their purported alleviating effects on respective characteristic symptom spectra, producing unsatisfactory patient responses. While drug profiles may differ concerning the underlying mechanism of action, the breadth of treatment options remains limited. Besides developing new drugs with different mechanisms of action, side-effect profile and efficacy, it has to be emphasized that repurposed drugs might serve as alternative or adjuvant treatment options for patients, who continue to poorly respond to standard treatment algorithms. Here, we review the current evidence of selected drugs whose repurposed use might expand the range of treatment options for schizophrenia and bipolar disorders.
Keywords: Medical need, antipsychotics, treatment resistance, adherence, oxytocin, omega-3 fatty acids.
Current Topics in Medicinal Chemistry
Title:Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Volume: 13 Issue: 18
Author(s): J. M. Bumb, F. Enning and F. M. Leweke
Affiliation:
Keywords: Medical need, antipsychotics, treatment resistance, adherence, oxytocin, omega-3 fatty acids.
Abstract: Characteristic symptoms of schizophrenia and bipolar disorders have been described and classified about a century ago. Each of these disorders may cause considerable impairment reflecting substantial alterations in cognition, perception, and mood. Though both disease concepts are well established, psychopharmacological treatment strategies, involving first- and second-generation antipsychotics, benzodiazepines and mood stabilizing drugs, often fail to keep their purported alleviating effects on respective characteristic symptom spectra, producing unsatisfactory patient responses. While drug profiles may differ concerning the underlying mechanism of action, the breadth of treatment options remains limited. Besides developing new drugs with different mechanisms of action, side-effect profile and efficacy, it has to be emphasized that repurposed drugs might serve as alternative or adjuvant treatment options for patients, who continue to poorly respond to standard treatment algorithms. Here, we review the current evidence of selected drugs whose repurposed use might expand the range of treatment options for schizophrenia and bipolar disorders.
Export Options
About this article
Cite this article as:
Bumb M. J., Enning F. and Leweke M. F., Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders, Current Topics in Medicinal Chemistry 2013; 13 (18) . https://dx.doi.org/10.2174/15680266113136660165
DOI https://dx.doi.org/10.2174/15680266113136660165 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Asthma Therapy
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Synthesis and Applications of Glyconanoparticles
Current Organic Chemistry In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants
Central Nervous System Agents in Medicinal Chemistry Sex Steroid Hormone Effects in Normal and Pathologic Conditions in Lung Physiology
Mini-Reviews in Medicinal Chemistry Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology Targeted Nanosystems for Cancer Therapy
Current Cancer Therapy Reviews Decreased Serum/Plasma Vitamin D levels in SLE Patients: A Meta-Analysis
Current Pharmaceutical Design Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Antimutagenic Activity of Lutein –An Oxycarotenoid Present in the Macula and its Inhibition of Cytochrome P 450 Enzymes in vitro
Drug Metabolism Letters The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Synthesis of a Novel Curcumin Derivative as a Potential Imaging Probe in Alzheimer’s Disease Imaging
Current Alzheimer Research Anticancer Activity and DNA Binding of 4-Alkylenediamines Modified Naphthalimide Derivatives
Letters in Drug Design & Discovery TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Medicinal Chemistry Approaches of Controlling Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs. Endogenous Protective Mechanisms and Drug Design
Medicinal Chemistry Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Current Medicinal Chemistry